Treatment of eye problems in Sjogren syndrome with Autologous Conditioned Serum

The effect of Autologous Conditioned Serum on eye condition in patients with Sjogren syndrome

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160422027520N16

Enrollment

Registered

2020-02-08

Start date

2020-01-20

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye in Sjogren syndrome. Sicca syndrome [Sjogren]

Interventions

Intervention 1: Intervention group: patients receiving Autologous Conditioned Serum (ACS) as the intervention group. blood was taken by ACS-specific syringe, manufactured by Orthokin Co., for ACS prep

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: People between the ages of 25-40 years Having Sjogren's Syndrome The availability of individual during the study period

Exclusion criteria

Exclusion criteria: Having a financial incentive to participate in the study or Participate in another study simultaneously Having eye problems for reasons other than Sjogren's syndrome People with malignancy People with diabetes

Design outcomes

Primary

Measure	Time frame
The effect of Autologous Conditioned Serum on eye condition in patients with Sjogren syndrome. Timepoint: 3 months after using autologous conditioned serum injection. Method of measurement: With tests: Tear film breakup time (tBUT), Best corrected visual acuity (BCVA), Fluorescein staining, Rose Bengal staining, Tear film meniscus.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Yousefi

Tabriz University of Medical Sciences

yousefime@tbzmed.ac.ir+98 41 3336 4665

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026